CST6

CST6 (cystatin E/M) is a secreted cysteine protease inhibitor that restrains tumor cell invasion and osteolytic bone destruction by inhibiting lysosomal cysteine proteases and the asparaginyl endopeptidase legumain through spatially distinct mechanisms (PMID:22688893, PMID:34815788, PMID:24742492). As a cancer cell-derived soluble factor, it suppresses breast cancer proliferation, migration, invasion and bone metastasis (PMID:22688893). In the bone microenvironment it acts non-cell-autonomously on osteoclasts: it is endocytosed into osteoclasts where it suppresses cathepsin B, leading to upregulation of its substrate SPHK1 and blockade of RANKL-induced p38 activation, thereby inhibiting osteoclast maturation (PMID:34815788); in multiple myeloma it inhibits cathepsin K and blocks cathepsin-mediated cleavage of NF-κB/p100 and TRAF3, attenuating monocyte polarization to osteoclast precursors (PMID:35881476). Intracellularly and independent of secretion or glycosylation, CST6 induces apoptosis in TBX2-expressing breast cancer cells specifically through legumain inhibition rather than cathepsin inhibition (PMID:24742492). CST6 transcription is controlled by opposing regulators — repressed by TBX2 and activated by EGR1, the latter downstream of an SRC/EGR1 axis — and is frequently silenced by CpG island promoter hypermethylation in breast and brain tumors (PMID:24742492, PMID:39695463, PMID:17043665, PMID:18607344). A homozygous loss-of-function mutation (p.Gly84Asp) that ablates cathepsin inhibitory activity causes a human skin cornification disorder, recapitulated as excessive cornification and impaired skin barrier in mice (PMID:36371786).

1. 2006 Medium

   Established why CST6 is lost in cancer by showing its silencing is epigenetic rather than mutational, defining a reversible mechanism of tumor suppressor inactivation.

   Evidence 5-aza-2'-deoxycytidine rescue and bisulfite sequencing across breast cancer cell lines

   PMID:17043665

   Open questions at the time

   • Did not test functional consequences of restored expression
   • Single lab, cell-line based
2. 2008 Medium

   Generalized the epigenetic silencing and anti-invasive role of CST6 beyond breast tissue to brain tumors, linking promoter hypermethylation to functional loss of motility suppression.

   Evidence Ectopic expression motility/invasion assays plus methylation-specific PCR, bisulfite sequencing, and tissue microarray IHC in gliomas

   PMID:18607344

   Open questions at the time

   • Molecular target of motility suppression not identified
   • No in vivo validation
3. 2012 High

   Demonstrated that CST6 is a secreted factor whose soluble form, derived from cancer cells, suppresses invasion and osteolytic bone metastasis, establishing it as a functional metastasis suppressor.

   Evidence Secretome proteomics with gain/loss-of-function and an in vivo bone metastasis model

   PMID:22688893

   Open questions at the time

   • Protease target mediating the anti-metastatic effect not pinpointed
   • Mechanism of bone protection not dissected
4. 2014 High

   Resolved that CST6 has a secretion-independent intracellular function, showing apoptosis induction depends on legumain inhibition rather than cathepsin inhibition, and placed CST6 under TBX2/EGR1 transcriptional control.

   Evidence Domain mutagenesis, LGMN activity assays, and siRNA knockdown in TBX2-expressing breast cancer cells

   PMID:24742492

   Open questions at the time

   • How CST6 accesses intracellular legumain not defined
   • Apoptotic effectors downstream of LGMN inhibition unresolved
5. 2021 High

   Defined a mechanistic pathway for bone protection by showing CST6 is endocytosed into osteoclasts to suppress CTSB, raising SPHK1 and blocking RANKL-induced p38, explaining how it inhibits osteoclastogenesis.

   Evidence Osteoclastogenesis assays, endocytosis tracking, recombinant protein and peptide screening, and preclinical metastasis models

   PMID:34815788

   Open questions at the time

   • Receptor/route of osteoclast endocytosis not identified
   • Quantitative contribution of SPHK1 axis versus other targets unclear
6. 2022 High

   Extended CST6's anti-osteoclastic mechanism to multiple myeloma by showing inhibition of cathepsin K and protection of NF-κB/p100 and TRAF3 from cathepsin cleavage, and linked it to suppressed monocyte-to-osteoclast polarization.

   Evidence Recombinant cathepsin K inhibition assays, ex vivo/in vivo myeloma bone models, and single-cell RNA-seq

   PMID:35881476

   Open questions at the time

   • Which cathepsin directly cleaves p100/TRAF3 in cells not isolated
   • Relative roles of CTSB versus cathepsin K across contexts unresolved
7. 2022 High

   Provided causal human and mouse genetic evidence that CST6 cathepsin-inhibitory activity is required for normal skin cornification, defining a Mendelian disease role.

   Evidence Whole-exome sequencing, fluorimetric inhibition assays of mutant protein against cathepsins V/L, and a mouse knock-in model with histopathology

   PMID:36371786

   Open questions at the time

   • Specific epidermal cathepsin substrate dysregulated in vivo not defined
   • Single family / single allele
8. 2024 Medium

   Mapped an upstream transcriptional circuit, showing SRC represses EGR1 which activates CST6, providing a druggable node (e.g. ketamine targeting SRC) to restore CST6-mediated bone protection.

   Evidence Co-culture osteoclastogenesis, immunoprecipitation, luciferase reporters of EGR1 and CST6 promoters, and intracardiac injection mouse model

   PMID:39695463

   Open questions at the time

   • Direct EGR1 binding to the CST6 promoter not footprinted at base resolution
   • Generality of the SRC/EGR1/CST6 axis beyond this model untested
9. 2024 Medium

   Demonstrated therapeutic sufficiency of CST6 for bone protection by showing CST6-secreting CAR-T cells prevent myeloma bone damage whereas equivalent CAR-T without CST6 do not, decoupling bone protection from tumor killing.

   Evidence BCMA-CST6 CAR-T engineering, in vitro osteoclastogenesis, and xenograft MM mouse model with micro-CT

   PMID:37883186

   Open questions at the time

   • Durability and systemic effects of secreted CST6 not characterized
   • Single lab proof-of-concept
10. 2025 Low

    Raised a context-dependent, potentially pro-pathogenic role for CST6, where hypoxia-induced CST6 enhances endothelial dysfunction markers and LGMN expression with TNFα in a preeclampsia model.

    Evidence Trophoblast stem cell differentiation, hypoxia exposure, and recombinant CST6 treatment of endothelial cells with mRNA analysis

    PMID:40234537

    Open questions at the time

    • Primarily expression-based with limited mechanistic follow-up
    • Direction of LGMN modulation appears opposite to cancer findings and is unreconciled
    • No in vivo validation

• How CST6 partitions between its extracellular cathepsin-directed and intracellular legumain-directed functions, and what determines its protective versus pathogenic effect across tissues, remains unresolved.
• No structural model explaining differential cathepsin versus legumain targeting in vivo
• Mechanism of cellular entry/trafficking not defined
• Context determinants of pro- versus anti-pathogenic activity unknown